论文部分内容阅读
目的观察替吉奥联合多西他赛治疗晚期胃癌的疗效和不良反应。方法选取晚期胃癌患者32例,采用替吉奥胶囊80mg/m2,每天2次,餐后口服,连服14d,休息7d;多西他赛75mg/m2,每个周期第1天,静脉滴注;至少化疗2个周期评价疗效和不良反应。结果 32例患者均可评价疗效,完全缓解2例,部分缓解11例,疾病稳定9例,疾病进展10例。客观有效率为40.6%,疾病控制率为68.8%,临床受益有效率为65.6%,疾病进展时间6.8个月,1年生存率73.6%。不良反应以骨髓抑制、恶心呕吐、神经毒性为主,可以耐受。结论替吉奥联合多西他赛治疗晚期胃癌有较好疗效,不良反应可耐受,值得临床应用。
Objective To observe the curative effect and adverse reactions of treatment of advanced gastric cancer with tegaserod and docetaxel. Methods Twenty-two patients with advanced gastric cancer were enrolled in this study. The patients were treated with TIGO 80mg / m2 twice a day for 2 days. After meal, they were given oral for 14 consecutive days and were rested for 7 days. Docetaxel 75 mg / m2 was given intravenously every day on the first day. ; At least two cycles of chemotherapy to evaluate the efficacy and adverse reactions. Results All 32 patients could evaluate the curative effect, complete remission in 2 cases, partial remission in 11 cases, stable disease in 9 cases and disease progression in 10 cases. Objectively effective rate was 40.6%, disease control rate was 68.8%, clinical benefit was 65.6%, disease progression time was 6.8 months, and 1-year survival rate was 73.6%. Adverse reactions to bone marrow suppression, nausea, vomiting, neurotoxicity-based, can be tolerated. Conclusion Treatment of advanced gastric cancer with tegaserod and docetaxel has good curative effect and adverse reactions are tolerable, which is worthy of clinical application.